 |
By the end of 2004 the world market for Colony Stimulating Factors
was valued at $3.6 billion, a growth of 11% over 2003. The market has
been growing at an average annual growth rate of 16% over the previous 5
years.
Amgen's Neupogen (Filgrastim) will lose its key patent in major markets
in 2006 opening the market for generics. Amgen is already preparing
itself for this major patent loss by concentrating its marketing efforts
on Neulasta (Peg-Filgrastim) its once-per-cycle long acting pegylated
product and by offering little or no support to Neupogen. |
|
 |
At the end of 2004 the world market for erythropoietin was valued at
$11.1 billion, a growth of 8% over 2003. The market has been growing at
an average annual growth rate of 18% over the previous 5 years.
The market for Erythropoietin is very lucrative. Marketing costs are low
due to the well-defined patient population and distribution costs are
low due to the limited distribution outlets. Since the market is a
virtual oligopoly barriers to entry are high thus insuring high
profitability.
|
|
 |
The global market for Monoclonal Antibody (Mab) Therapeutics reached
a total of $11.2 billion in 2004. The market has been growing at an
impressive compound average annual growth rate of 42% over the previous
five years.
|
|
 |
The biopharmaceutical market has come along way since 1982 when the
first biopharmaceutical product, recombinant human insulin, was
launched. Over 130 such products are currently being marketed around the
world including thirteen blockbuster drugs.
|
|
 |
At the end of 2004 the world market for Interferon was valued at
$5.9 billion, a growth of 13% over 2003. The market has been growing at
an average annual growth rate of 17% over the previous 5 years.
The interferon market is application driven and clearly demarcated along
the lines of the type of the interferon molecule. At 60% share,
interferon Beta accounts for the main bulk of the market followed by
interferon Alfa at 37% market share |
|
